Event Details:

• Date:  12 PM to 3 PM, April 4, 2025
• Location: University of Kiel, Institute of Biochemistry, Kiel, Germany
• Host: Prof. Dr. Elmar Wolf, Chair of Biochemistry and Molecular Biology (Research Group Website)

• Date:  12:30 PM to 2 PM, April 8, 2025
• Location: Paris-Cardiovascular Research Center (PARCC)
• Host: Prof Pierre-Louis Tharaux

• Date:  12 PM to 3 PM, April 11, 2025
• Location: Uppsala University, Department of Immunology
  
• Host: Prof Lena Claesson-Welsh

Overview

Generating complex genomically engineered mouse models for biomedical research is often challenging and time-consuming. In this presentation, Dr. Ouyang explores traditional ES cell homologous recombination and Targeted Gene Editing-mediated genome editing techniques for gene targeted animal model generation. He also introduces Cyagen’s extensive catalog of ready-to-use KO/cKO off-the-shelf mouse models developed using these technologies.

A key highlight of the presentation is Cyagen’s proprietary TurboKnockout platform, the latest ES-cell-based gene targeting technology. TurboKnockout enables the creation of complex genomically modified mouse models in as fast as 6 months, reducing timelines by 4-6 months compared to traditional approaches.

Finally, Dr. Ouyang will discuss Cyagen’s genomically humanized mouse models for gene therapy (HUGO-GT) and antibody discovery (HUGO-Ab) programs, in which the mouse gene is replaced with the full-length human gene, including exons, introns, and UTRs. He will highlight their applications in biomedical research, with a particular focus on cancer and rare disease gene therapy studies.

Who Should Attend?

• Researchers in oncology, immunology, and neuroscience
• Pharmaceutical scientists involved in drug development
• Clinical researchers focused on gene therapy
• Geneticists interested in rare diseases
• Students in biomedical fields
• Industry professionals in biotech

Speaker:

Yingbin (Marvin) Ouyang, MD, PhD

Executive Vice President and Chief Scientific Officer, Cyagen

Dr. Marvin Ouyang has over 25 years of experience in developing genetically engineered mice. Prior to joining Cyagen in 2012, he held senior research positions at the Oklahoma Medical Research Foundation, Thios Pharmaceuticals, and Taconic Biosciences. Throughout his career, he has successfully created thousands of transgenic and gene knockout/knockin mouse and rat models. His work has been published in high-impact journals such as PNAS and JBC, and his technical contributions have been directly cited by Nature and other international journals hundreds of times.

About Cyagen:

Founded in 2006, Cyagen is a leading provider of custom cell and animal models, as well as comprehensive CRO services to accelerate preclinical research and drug development. We offer a one-stop platform for model generation, including phenotyping, functional validation, and pathological analysis.

Our proprietary genetic modification technologies—Targeted Gene Editing-Pro, TurboKnockout, and PiggyBac-on-BAC transgenics—enable efficient disease model development, while our Knockout Catalog Models feature over 16,000 ready-to-use KO/cKO mouse strains. Cyagen’s innovative platforms include fully humanized genomic ortholog (HUGO) Mice for Gene Therapy (HUGO-GT) and Antibody Discovery (HUGO-Ab), AI platforms to accelerate preclinical CGT research, AAV discovery, and drug efficacy studies.

With expertise in custom model development, CGT, rare disease research, and gene therapy, Cyagen supports global scientists with cutting-edge tools and services. Contact us for a free consultation.

Register Now

For inquiries, contact us at animal-service@cyagen.com.